Skip to content
value.today

Hoth Therapeutics, Inc.

🇺🇸 New York, New York, USAPharmaceuticalsFounded 2017
Total raised
$3 M
2 rounds on record
Latest round
$2 M
Aug 2019
First round on record
Oct 2017
Today
Went public
See the company page

Hoth Therapeutics, Inc. is listed today as Rocket One Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Hoth Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2023$10 MPrivate placement after listing$10 to $50 million

Hoth Therapeutics, Inc.: Private sale, Jan 2023

Investors in this round

1 investor had bought by the notice of Jan 4, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Hoth Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$700,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • David Briones · Executive Officer · Chief Financial Officer
  • Robb Knie · Executive Officer, Director · Chief Executive Officer and President
  • David Sarnoff · Director
  • Graig Springer · Director
  • Jeff Pavell · Director
  • Wayne Linsley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “Represents a fee of 7% of the gross proceeds from the sale of securities. Excludes (i) a management fee of $100,000; (ii) non-accountable expenses of $20,000; (iii) accountable expenses of $50,000; and (iv) 100,000 placement agent warrants.”

Signed by Robb Knie, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 4, 2023. Read the notice at the SEC.

equity, optionsSEC
Mar 2021$15 MPrivate placement after listing$10 to $50 million

Hoth Therapeutics, Inc.: Private sale, Mar 2021

Investors in this round

13 investors had bought by the notice of Mar 16, 2021: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Hoth Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,050,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • David Briones · Executive Officer · Chief Financial Officer
  • Robb Knie · Executive Officer, Director · Chief Executive Officer and President
  • Stefanie Johns · Executive Officer · Chief Scientific Officer
  • David Sarnoff · Director
  • Graig Springer · Director
  • Vadim Mats · Director
  • Wayne Linsley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in IL, NJ, NY

Remarks in the notice

  • On fees: “Represents a fee of 7% of the gross proceeds from the sale of securities. Excludes (i) a management fee of $150,000; (ii) non-accountable expenses of $35,000; (iii) accountable expenses of $50,000; and (iv) 379,747 placement agent warrants.”

Signed by Robb Knie, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 16, 2021. Read the notice at the SEC.

equity, optionsSEC
Jan 2021$5 MPrivate placement after listing$2 to $10 million

Hoth Therapeutics, Inc.: Private sale, Jan 2021

Investors in this round

3 investors had bought by the notice of Jan 8, 2021: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Hoth Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$350,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • David Briones · Executive Officer · Chief Financial Officer
  • Robb Knie · Executive Officer, Director · Chief Executive Officer and President
  • Stefanie Johns · Executive Officer · Chief Scientific Officer
  • David Sarnoff · Director
  • Graig Springer · Director
  • Vadim Mats · Director
  • Wayne Linsley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • The Benchmark Company, LLC (CRD 22982) · New York, New YorkSold in CA, IL, NY

Remarks in the notice

  • On fees: “Represents a fee of 7% of the gross proceeds from the sale of securities. Excludes reimbursement of legal expenses in the amount of $50,000 and placement agent warrants to purchase common stock equal to 5% of the securities issued in the offering.”

Signed by Robb Knie, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 8, 2021. Read the notice at the SEC.

equity, optionsSEC
Aug 2019$2 MNo. 2$2 to $10 million

Hoth Therapeutics, Inc.: Raise no. 2, Aug 2019

Investors in this round

53 investors had bought by the notice of Aug 21, 2019: 53 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Hoth Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $5 M offered; $3 M still to sell
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$294,455
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • David Briones · Executive Officer
  • Robb Knie · Executive Officer, Director
  • Anthony Hayes · Director
  • David B. Sarnoff · Director
  • Kenneth Rice · Director
  • Vadim Mats · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in CA, FL, GA, IL, KY, LA, MA, MI, NC, NY, OK, PA, TX, UT, and outside the US

Remarks in the notice

  • On fees: “Laidlaw will also receive warrants to purchase such number of shares of common stock equal to 10% of the number of shares of common stock sold in the offering, including shares of common stock issuable upon exercise of warrants sold in the offering.”

Signed by Robb Knie, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 21, 2019. Read the notice at the SEC.

equity, optionsSEC
Oct 2017$1 MNo. 1Under $2 million

Hoth Therapeutics, Inc.: Raise no. 1, Oct 2017

Investors in this round

5 investors had bought by the notice of Nov 7, 2017: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Hoth Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $5 M offered; $4 M still to sell
Smallest investment taken
$10,000
What was sold
options or other rights to buy securities, securities to be acquired by exercising them, other: convertible preferred stock and warrants to purchase common stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$650,000
Finders' fees
none
Paid to its own people
$150,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • Robb Knie · Executive Officer, Director, Promoter · President and Chief Executive Officer
  • Anthony Hayes · Director
  • Kenneth Rice · Director
  • Vadim Mats · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in CO, ID, NJ, WI, and outside the US

Remarks in the notice

  • On fees: “Laidlaw & Company (UK) Ltd. will receive a one-time activation fee of $50,000 and a cash commission and a non-accountable expense equal to 10% and 2%, respectively, of the aggregate gross proceeds.”
  • On the use of proceeds: “To be used for payment of salary and board member fees.”

Signed by Robb Knie, President and CEO. Source: SEC Form D, newest notice filed Nov 7, 2017. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Hoth Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2023).

    SEC Form D · Jan 2023

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2023

That is all the official record says: Hoth Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Hoth Therapeutics, Inc. are on record.

Investors#

2 named in official filings. Open an investor to see everything it has backed.

Investors in Hoth Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Kevin Jess PoorPersonnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Matthew D. EitnerPersonnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 53 investors.

Largest shareholders today

Institutions holding Rocket One Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Hoth Therapeutics, Inc.
NameRoleNamed in
David BrionesChief Financial OfficerJan 2023
Robb KnieChief Executive Officer and PresidentJan 2023
Stefanie JohnsChief Scientific OfficerMar 2021
David SarnoffDirectorJan 2023
Graig SpringerDirectorJan 2023
Jeff PavellDirectorJan 2023
Robb KnieChief Executive Officer and PresidentJan 2023
Wayne LinsleyDirectorJan 2023
Vadim MatsDirectorMar 2021
Anthony HayesDirectorAug 2019
David B. SarnoffDirectorAug 2019
Kenneth RiceDirectorAug 2019
Robb KniePresident and Chief Executive OfficerNov 2017

Went public since 2019. Its SEC number is that of a company listed on a stock exchange.